CMS announced today that low-dose computed tomography screening will now be reimbursed once a year by Medicare as a preventive service benefit, despite an advisory panel recommending against the screening back in April 2014.
Medicare announced today that it will cover low-dose computed tomography (LDCT) screening. The memo released today by CMS states that the available evidence is sufficient to include preventive LDCT once a year as an additional preventive service benefit. The coverage benefit, of course, has to be met with certain criteria that have been laid down by the CMS. The beneficiary must be:
Further, the initial screen would require a written order for LDCT during a lung cancer screening counseling and shared decision making visit, furnished by a physician or qualified physician practitioner. For subsequent screens, the beneficiary must receive a written order, which may be furnished during any appropriate visit with a physician or qualified physician practitioner.
Additionally, the screening radiologist and the imaging center have to meet certain eligibility criteria for the coverage decision to be made.
This announcement contradicts the recommendation by a CMS advisory panel back in April 2014. The panel concluded that annual LDCT lung cancer screening for high-risk individuals doesn't have enough evidence for benefit over harms to be covered by.
The proposed coverage decision is now open for public comments.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Cancer Labels on Alcohol? Ireland, Where Pubs Still Rule, Will Have Them by Next Year
March 17th 2025As St. Patrick's Day brings global celebrations involving alcohol, Ireland looks forward to rethinking excess consumption with a new tool set to arrive next year: the world's most comprehensive alcohol warning label.
Read More